Cell-free DNA Methylation for Endometrial Cancer
Cell-free DNA Methylation for the Diagnosis and Monitoring of Endometrial Cancer: The Training and Validation Sets in China
Liquid biopsy is challenging for the diagnosis of endometrial cancer. In this study, investigators perform the methylation testing of host DNA, namely, BHLHE22, CELF4, HAND2, and ZNF177, in the peripheral serum to discover the diagnostic and supervision roles of DNA methylation in endometrial cancer. The study compromises two stages. In the training set, DNA methylation testing is performed in the endometrial tissues from patients with endometrial cancer and paired benign uterine lesions. The cut-off values of methylation are produced in this stage. On the meantime, DNA methylation testing is also performed in serum and in cervical cytology to reveal its accordance and accuracy compared with the results of endometrial tissues. In the validation set, serum DNA methylation testing is performed in unselected patients with definite endometrial histology to validate its accuracy. In training and validation sets, serum DNA methylation is also performed after major surgeries for endometrial cancer as to illustrate the changes of methylation testing, therefore, reflection the supervision role of DNA methylation.
Cut-off values of targeted DNA methylation in endometrial cancer
Accuracy of serum DNA methylation in endometrial cancer
DNA methylation testing
Study Arms / Comparison Groups
Description: All eligible participants consenting to participate the study.
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
December 18, 2020
January 1, 2023
Primary Completion Date
January 1, 2023
Inclusion Criteria: - With definite histological diagnosis of endometrial cancer and paired benign uterine tumor in training set, and with definite histological diagnosis of uterine tumor in validation set. - With sufficient fresh peripheral serum, cervical cytology, and endometrial samples for DNA methylation testing before with or without after major surgeries. - Aged 18 years or older. - Signed an approved informed consents Exclusion Criteria: - Not meeting all of the inclusion criteria.
18 Years - N/A
Accepts Healthy Volunteers
Lei Li, M.D., +8613911988831, [email protected]
Lei Li, M.D., Principal Investigator, Peking Union Medical College Hospital